Marengo Therapeutics to Present Clinical Data on Invikafusp Activity

Marengo Therapeutics to Present Clinical Data on Invikafusp Activity

Overview of the Presentation:

Marengo Therapeutics, Inc. a clinical-stage biotech company, is poised to share pivotal clinical data regarding its leading candidate, invikafusp alfa (STAR0602). This data stems from the STARt-001 trial, highlighting the agent's single-agent anti-tumor activity, particularly focusing on patients with PD1-resistant tumors. During the upcoming American Association of Cancer Research (AACR) Annual Meeting, set for April 2025, these crucial findings will be unveiled during a clinical plenary oral presentation.

Details of the Clinical Study Presentation

The clinical presentation will occur during the conference and will delve into the essential outcomes from the STARt-001 trial. This trial is instrumental as it marks a phase 1/2 evaluation of invikafusp alfa in patients who have exhibited resistance to existing PD1 therapies.

Presentation Information

• Title: Updated Clinical Results, Recommended Phase 2 Dose (RP2D) Determination, and Translational Study Results for STARt-001
• Conference: AACR Annual Meeting 2025
• Abstract Number: CT205
• Session Title: Clinical Trials Plenary: Biologics and T-cell Engagers
• Date and Time: Tuesday, April 29, 2025, 10:15 AM - 12:15 PM
• Presenter: Dr. Ryan J. Sullivan, Massachusetts General Hospital

About Marengo Therapeutics

Marengo Therapeutics is at the forefront of developing breakthrough immunotherapies. The company specializes in innovative T-cell activating therapies aimed at treating cancer and autoimmune disorders. By employing their proprietary technologies, the firm aims to strategically engage T cells to combat malignancies effectively.

The STAR™ Platform Explained

The STAR™ platform developed by Marengo Therapeutics represents a significant technological advancement in antibody-based therapies. This multi-specific antibody-fusion platform is derived from a library of antibodies that target specific regions of the T-cell receptor. By fusing these antibodies with co-stimulatory signals, the platform seeks to foster stronger and more durable immune responses against tumors.

About Invikafusp alfa (STAR0602)

Invikafusp alfa, as the flagship candidate from the STAR™ platform, is engineered to selectively activate vital T cell subsets present in various cancers. This unique mechanism of action supports the proliferation of potent, memory T cells, leading to enhanced anti-tumor activity and potentially long-lasting resistances against tumor recurrence.

Understanding the STARt-001 Clinical Study

The STARt-001 trial is a comprehensive phase 1/2 study aimed at assessing the safety and preliminary efficacy of invikafusp alfa in patients who have advanced antigen-rich solid tumors. Notably, this includes those who show resistance to PD-1 therapies and other less common tumors. It comprises two sequential parts: a dose escalation phase followed by a dose expansion utilized to further evaluate the drug’s effectiveness.

Frequently Asked Questions

What is the focus of the STARt-001 trial?

The STARt-001 trial is focused on evaluating the safety and efficacy of invikafusp alfa in patients with advanced solid tumors that are resistant to PD1 inhibitors.

When will Marengo present the updated data?

The updated clinical data will be presented during the AACR Annual Meeting on April 29, 2025.

Who will present the findings?

The findings will be presented by Dr. Ryan J. Sullivan from Massachusetts General Hospital.

What is invikafusp alfa?

Invikafusp alfa is a novel therapy designed to activate specific T cell populations to enhance anti-tumor immune responses.

How can patients participate in the study?

Patients can inquire about participation by contacting cancer research networks or visiting relevant clinical trial websites.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.